The search was carried out in Medline (1966 – March Week 1, 2009). The Cochrane Renal Group Trials Register was also searched for trials not indexed in Medline. Date of searches: 9 March 2009. The beneficial effect of DST in one haplotype mismatch living related donors was first suggested by Salvatierra et al.2 Since then, two prospective randomized trials have been reported.3,4

Alexander et al.3 compared patients given DST 24 hours prior to transplant and 7–10 days post-transplant (n = 115) with patients who did not receive DST (n = 97). The immunosuppression regimen was routine triple immunosuppression commenced post-transplant. All patients were -HLA non-identical (>50% had more than two Class I mismatches and more than one Class II mismatch). There was a similar distribution of AZD1208 research buy HLA mismatch between the two groups. Biopsy-proven rejection episodes were seen more frequently in the DST group (81 vs 54 in non-DST) but this difference was not statistically significant. A significantly higher creatinine level was seen in the DST group at 7 and 14 days but this did not translate into a difference in 1- or 2-year graft survival. One of the primary outcomes of the study

was the ability to withdraw steroid treatment; no significant difference was seen between Tanespimycin concentration the two groups for this outcome. There was no difference in adverse events between the two groups. Limitations of this study include the inclusion of a diverse degree of HLA matches and too small a sample size to adequately study the effect of DST for the different HLA matches. In a smaller prospective trial, Sharma et al.4 randomized living related recipients (n = 15) to receive DST (one transfusion 24 hours prior

to transplant) or no DST (n = 15). All patients received cyclosporine 3 days prior to transplant and continued routine triple therapy post-transplant. In addition, all patients received third-party transfusions 2–3 weeks 17-DMAG (Alvespimycin) HCl prior to transplantation to correct anaemia. Sharma et al. found a significantly greater incidence of acute rejection in the non-DST group (1.1 vs 0.26 per patient, P < 0.01). A significantly lower creatinine level was also seen in the DST group from 3 months to 12 months post-transplant (at 12 months, 1.12 vs 2.02 mg/dL, P < 0.05). However, there was no difference in graft survival in the short term (1 year). It is difficult to extrapolate results from this study to current practice because the degree of HLA match was not specified and patients in both groups received third-party transfusions to correct anaemia (prior to standard erythropoietin usage). Bordes-Aznar et al.